芬兰医疗技术公司Bioretec通过FDA的突破性设备指标加快RemeOsTM脊柱间体开发,预计到2028年销售额将达到6500万欧元. Finnish medical tech firm Bioretec fast-tracks RemeOs™ Spinal Interbody Cage development with FDA's Breakthrough Device designation, predicting €65M sales by 2028.
芬兰的一家医疗技术公司Bioretec正在快速开发它的RemeOsTM Spinal Interbody Cage,其目的是提高脊椎外科手术的结果。 Bioretec, a Finnish medical tech firm, is fast-tracking the development of its RemeOs™ Spinal Interbody Cage, which is designed to enhance spinal surgery outcomes. 这一装置是由一种可吸收的磁共振和磁共振兼容的镁合金制成的,旨在通过解决与传统植入物有关的问题,改善病人的康复。 This device, made from an MRI-compatible, absorbable magnesium alloy, aims to improve patient recovery by addressing issues with traditional implants. 随着FDA的突破性设备指标,Bioretec更新了其财务目标,预计到2028年销售额将达到6500万欧元. Following FDA's Breakthrough Device designation, Bioretec has updated its financial targets, forecasting €65 million in sales by 2028.